A clinical trial of autologous stem cell transplantation for severe systemic sclerosis
A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis - A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for ...
systemic sclerosis
After peripheral blood stem cell mobilization and aphereisi with cyclophosphamide 4 g/m2 and G-CSF, CD34+ cells were enriched by using anti-CD34 immunomagnetic beads. Conditioning was performed using high-dose cyclophosphamide (50 mg/kg) for 4 days, and freeze-thawed CD34+ cells were transplanted. After peripheral blood stem cell mobilization and aphereisi with cyclophosphamide4 g/m2 and G-CSF, C ...
Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfu ...
Open-label trial of granulocyte-colony stimulating factor (G-CSF) for evaluating efficacy on peripheral vascular disease in patients with systemic sclerosis Open-label trial of granulocyte-colony stimulating factor (G-CSF) for evaluating efficacy on periphe ...
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected ...